DexCom Inc (DXCM) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
Total Cash From Operating Activities Chart for DexCom Inc
DexCom Inc (DXCM) operating cash flow for FY2025 was USD 1.4B, a 45.6% change from FY2024. DexCom Inc's operating cash flow moved from USD -9.5M in 2003 to USD 1.4B in 2025 over 22 years. Operating cash flow compound annual growth rate: 5-year CAGR of 24.8%, 10-year CAGR of 40.2%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $31.19B
- Implied Share Price
- $82.66
- Enterprise Value
- $32.26B
- Revenue (TTM)
- $4.97B
- EBITDA
- $1.40B
- Profit Margin
- 20.12%
- Trailing P/E
- 32.67
- Forward P/E
- 34.36
- Price/Book (MRQ)
- 12.52
- Price/Sales (TTM)
- 6.30
- EV/EBITDA
- 20.69
- EV/Revenue
- 6.49
- Dividend Yield
- —
- Book Value
- $6.95
- Free Cash Flow (FY2025)
- $1.08B
- Free Cash Flow Yield
- 3.45%
Snapshot as of 5th August 2026 — not point-in-time controlled, may lag the live market by a few days.